Citadel Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-407,800
| Closed | -$1.24M | – | 15987 |
|
|
2024
Q4 | $1.24M | Buy |
407,800
+361,200
| +775% | +$1.57M | ﹤0.01% | 6579 |
|
|
2024
Q3 | $242K | Sell |
46,600
-13,500
| -22% | -$67.1K | ﹤0.01% | 9750 |
|
|
2024
Q2 | $154K | Buy |
60,100
+1,100
| +2% | +$3.76K | ﹤0.01% | 10304 |
|
|
2024
Q1 | $290K | Sell |
59,000
-12,500
| -17% | -$74K | ﹤0.01% | 9511 |
|
|
2023
Q4 | $628K | Sell |
71,500
-44,300
| -38% | -$363K | ﹤0.01% | 7615 |
|
|
2023
Q3 | $1.33M | Buy |
115,800
+63,700
| +122% | +$1.22M | ﹤0.01% | 6010 |
|
|
2023
Q2 | $1.32M | Buy |
52,100
+2,500
| +5% | +$77.9K | ﹤0.01% | 5907 |
|
|
2023
Q1 | $1.6M | Sell |
49,600
-34,000
| -41% | -$1.06M | ﹤0.01% | 5791 |
|
|
2022
Q4 | $1.54M | Sell |
83,600
-171,500
| -67% | -$3.92M | ﹤0.01% | 5977 |
|
|
2022
Q3 | $6.89M | Buy |
255,100
+205,800
| +417% | +$4.17M | ﹤0.01% | 3346 |
|
|
2022
Q2 | $681K | Sell |
49,300
-27,000
| -35% | -$416K | ﹤0.01% | 7939 |
|
|
2022
Q1 | $1.49M | Buy |
76,300
+52,100
| +215% | +$790K | ﹤0.01% | 6743 |
|
|
2021
Q4 | $395K | Sell |
24,200
-255,900
| -91% | -$4.27M | ﹤0.01% | 10259 |
|
|
2021
Q3 | $7.8M | Buy |
280,100
+11,300
| +4% | +$322K | ﹤0.01% | 3499 |
|
|
2021
Q2 | $7.97M | Buy |
268,800
+11,900
| +5% | +$343K | ﹤0.01% | 3501 |
|
|
2021
Q1 | $7.18M | Sell |
256,900
-58,700
| -19% | -$1.62M | ﹤0.01% | 3525 |
|
|
2020
Q4 | $8.94M | Sell |
315,600
-300
| -0.1% | -$7.77K | ﹤0.01% | 2799 |
|
|
2020
Q3 | $7.94M | Buy |
315,900
+300,400
| +1,938% | +$7.88M | ﹤0.01% | 2570 |
|
|
2020
Q2 | $379K | Sell |
15,500
-700
| -4% | -$13.8K | ﹤0.01% | 7535 |
|
|
2020
Q1 | $240K | Sell |
16,200
-2,300
| -12% | -$47.6K | ﹤0.01% | 7705 |
|
|
2019
Q4 | $300K | Buy |
18,500
+7,800
| +73% | +$121K | ﹤0.01% | 7586 |
|
|
2019
Q3 | $139K | Buy |
+10,700
| New | +$131K | ﹤0.01% | 8338 |
|
|
2019
Q1 | – | Sell |
-11,100
| Closed | -$223K | – | 9991 |
|
|
2018
Q4 | $223K | Sell |
11,100
-400
| -3% | -$8.81K | ﹤0.01% | 7710 |
|
|
2018
Q3 | $286K | Sell |
11,500
-5,000
| -30% | -$136K | ﹤0.01% | 7648 |
|
|
2018
Q2 | $453K | Sell |
16,500
-1,300
| -7% | -$39.1K | ﹤0.01% | 6532 |
|
|
2018
Q1 | $548K | Sell |
17,800
-2,300
| -11% | -$74K | ﹤0.01% | 5740 |
|
|
2017
Q4 | $719K | Buy |
20,100
+11,600
| +136% | +$333K | ﹤0.01% | 5117 |
|
|
2017
Q3 | $234K | Buy |
+8,500
| New | +$206K | ﹤0.01% | 6466 |
|
Other funds holding RVNC
Citadel Advisors's RVNC Position: Q1 2025 in Review
Citadel Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 91,118 shares — an estimated $277K sold.
Citadel Advisors first reported a position in RVNC in Q1 2014 and held it in 33 quarters. The position peaked at $13M in Q1 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Citadel Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 91,118 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $277K.
- Citadel Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 33 quarters.
- Citadel Advisors's Revance Therapeutics, Inc. position peaked at $13M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.